|
1
|
Scheffer GL, Wijngaard PL, Flens MJ,
Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and
Scheper RJ: The drug resistance-related protein LRP is the human
major vault protein. Nat Med. 1:578–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scheper RJ, Broxterman HJ, Scheffer GL,
Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML,
de Vries EG, van der Valk P, Meijer CJ and Pinedo HM:
Overexpression of a M(r) 110,000 vesicular protein in
non-P-glycoprotein-mediated multidrug resistance. Cancer Res.
53:1475–1479. 1993.PubMed/NCBI
|
|
3
|
Scheffer GL, Schroeijers AB, Izquierdo MA,
Wiemer EA and Scheper RJ: Lung resistance-related protein/major
vault protein and vaults in multidrug-resistant cancer. Curr Opin
Oncol. 12:550–556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kitazono M, Sumizawa T, Takebayashi Y,
Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and
Akiyama S: Multidrug resistance and the lung resistance-related
protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst.
91:1647–1653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pohl G, Suchomel RW, Stranzl T, Depisch D,
Stiglbauer W, Filipits M and Pirker R: Expression of the lung
resistance protein in primary colorectal carcinomas. Anticancer
Res. 21:201–204. 2001.PubMed/NCBI
|
|
6
|
Meijer GA, Schroeijers AB, Flens MJ,
Meuwissen SG, van der Valk P, Baak JP and Scheper RJ: Increased
expression of multidrug resistance related proteins Pgp, MRP1, and
LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol.
52:450–454. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ikeda R, Iwashita K, Sumizawa T, Beppu S,
Tabata S, Tajitsu Y, Shimamoto Y, Yoshida K, Furukawa T, Che XF,
Yamaguchi T, Ushiyama M, Miyawaki A, Takeda Y, Yamamoto M, Zhao HY,
Shibayama Y, Yamada K and Akiyama S: Hyperosmotic stress
up-regulates the expression of major vault protein in SW620 human
colon cancer cells. Exp Cell Res. 314:3017–3026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugawara I, Akiyama S, Scheper RJ and
Itoyama S: Lung resistance protein (LRP) expression in human normal
tissues in comparison with that of MDR1 and MRP. Cancer Lett.
112:23–31. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lange C, Walther W, Schwabe H and Stein U:
Cloning and initial analysis of the human multidrug
resistance-related MVP/LRP gene promoter. Biochem Biophys Res
Commun. 278:125–133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asakuno K, Kohno K, Uchiumi T, Kubo T,
Sato S, Isono M and Kuwano M: Involvement of a DNA binding protein,
MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D.
Biochem Biophys Res Commun. 199:1428–1435. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohga T, Uchiumi T, Makino Y, Koike K, Wada
M, Kuwano M and Kohno K: Direct involvement of the Y-box binding
protein YB-1 in genotoxic stress-induced activation of the human
multidrug resistance 1 gene. J Biol Chem. 273:5997–6000. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stein U, Jürchott K, Walther W, Bergmann
S, Schla PM and Royer HD: Hyperthermia-induced nuclear
translocation of transcription factor YB-1 leads to enhanced
expression of multidrug resistance-related ABC transporters. J Biol
Chem. 276:28562–28569. 2001. View Article : Google Scholar
|
|
13
|
Steiner E, Holzmann K, Pirker C, Elbling
L, Micksche M, Sutterlüty H and Berger W: The major vault protein
is responsive to and interferes with interferon-γ-mediated STAT1
signals. J Cell Sci. 119:459–469. 2006.
|
|
14
|
Steiner E, Holzmann K, Pirker C, Elbling
L, Micksche M and Berger W: SP-transcription factors are involved
in basal MVP promoter activity and its stimulation by HDAC
inhibitors. Biochem Biophys Res Commun. 317:235–243. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sawadogo M, Van Dyke MW, Gregor PD and
Roeder RG: Multiple forms of the human gene-specific transcription
factor USF. I Complete purification and identification of USF from
HeLa cell nuclei. J Biol Chem. 263:11985–11993. 1988.
|
|
16
|
Sawadogo M: Multiple forms of the human
gene-specific transcription factor USF. II DNA binding properties
and transcriptional activity of the purified HeLa USF. J Biol Chem.
263:11994–12001. 1988.PubMed/NCBI
|
|
17
|
Gregor PD, Sawadogo M and Roeder RG: The
adenovirus major late transcription factor USF is a member of the
helix-loop-helix group of regulatory proteins and binds to DNA as a
dimer. Genes Dev. 4:1730–1740. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sirito M, Walker S, Lin Q, Kozlowski MT,
Klein WH and Sawadogo M: Members of the USF family of
helix-loop-helix proteins bind DNA as homo- as well as
heterodimers. Gene Expr. 2:231–240. 1992.PubMed/NCBI
|
|
19
|
Miyamoto NG, Moncollin V, Wintzerith M,
Hen R, Egly JM and Chambon P: Stimulation of in vitro transcription
by the upstream element of the adenovirus-2 major late promoter
involves a specific factor. Nucleic Acids Res. 12:8779–8799. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu YT and Manley JL: Generation and
functional analyses for base substitution mutants of the adenovirus
2 major late promoter. Nucleic Acids Res. 12:9309–9321. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sirito M, Lin Q, Maity T and Sawadogo M:
Ubiquitous expression of the 43- and 44-kDa forms of transcription
factor USF in mammalian cells. Nucleic Acids Res. 22:427–433. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimamoto Y, Sumizawa T, Haraguchi M,
Gotanda T, Jueng HC, Furukawa T, Sakata R and Akiyama S: Direct
activation of the human major vault protein gene by DNA-damaging
agents. Oncol Rep. 15:645–652. 2006.PubMed/NCBI
|
